ACR–ACNM–ARS–SNMMI PRACTICE PARAMETER FOR THE PERFORMANCE OF THERAPY WITH RADIUM-223 DICHLORIDE
PREAMBLE
I. INTRODUCTION
II. PHYSICAL PROPERTIES
III. INDICATIONS
IV. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL
V. SPECIFICATIONS OF THE EXAMINATION AND TREATMENT
V. SPECIFICATIONS OF THE EXAMINATION AND TREATMENT
A. General Procedures
1. Clinical Evaluation
V. SPECIFICATIONS OF THE EXAMINATION AND TREATMENT
A. General Procedures
2. Quality Management
V. SPECIFICATIONS OF THE EXAMINATION AND TREATMENT
A. General Procedures
3. Informed Consent
V. SPECIFICATIONS OF THE EXAMINATION AND TREATMENT
A. General Procedures
4. Procedure
V. SPECIFICATIONS OF THE EXAMINATION AND TREATMENT
A. General Procedures
5. Radiation precautions
V. SPECIFICATIONS OF THE EXAMINATION AND TREATMENT
A. General Procedures
6. Published Clinical Reports
V. SPECIFICATIONS OF THE EXAMINATION AND TREATMENT
A. General Procedures
7. Clinical Investigation in additional Neoplasms
VI. DOCUMENTATION
VII. ACR STATEMENT ON THERAPEUTIC USE OF UNSEALED RADIOPHARMACEUTICAL SOURCES
VIII. RADIATION SAFETY
ACKNOWLEDGEMENTS
Writing Committee – members represent their societies in the initial and final revision of this practice parameter
|
|
|
|
Committee on Practice Parameters – Nuclear Medicine and Molecular Imaging
(ACR Committee responsible for sponsoring the draft through the process)
Committee on Practice Parameters and Technical Standards
(ACR Committee responsible for sponsoring the draft through the process)
Committee on Practice Parameters – Radiation Oncology
(ACR Committee responsible for sponsoring the draft through the process)
Comments Reconciliation Committee
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REFERENCES